Analyst firms · Morgan Stanley · RPRX
Morgan Stanley RPRX price target and rating history
Royalty Pharma plc (RPRX) · Health Care
Morgan Stanley rates Royalty Pharma plc (RPRX) Overweight with a $51 price target, as of its latest action on May 16, 2025. It has published 3 rating actions on RPRX since August 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Overweight
- Price target
- $51
- Median target, all firms
- Too few
- Actions on RPRX
- 3
Morgan Stanley price target on RPRX
Every Morgan Stanley rating on RPRX
- May 16, 2025
- Apr 6, 2022
- Aug 16, 2021
Questions about Morgan Stanley and RPRX
- What is Morgan Stanley's price target for RPRX?
- Morgan Stanley's latest stated price target for Royalty Pharma plc (RPRX) is $51, from its action on May 16, 2025.
- What is Morgan Stanley's rating on RPRX?
- Morgan Stanley rates RPRX Overweight, a bullish rating, as of May 16, 2025.
- When did Morgan Stanley last change its view on RPRX?
- On May 16, 2025, Morgan Stanley starts coverage at Overweight, price target $51.
More RPRX rating histories
All Morgan Stanley ratingsRPRX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.